SCHEMBL4563384

SCHEMBL4563384

C=CCOC(C(=O)O)C(=O)O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FNTA P49354 1/20 0.43
FNTB P49356 1/20 0.43
GRIK1 P39086 2/20 0.33
GRIK2 Q13002 2/20 0.33
CYP3A4 P08684 1/20 0.33
TDP1 Q9NUW8 1/20 0.32
CYP2C19 P33261 1/20 0.32
CPA1 P15085 1/20 0.32
TSHR P16473 2/20 0.31
MAPT P10636 1/20 0.31
CACNA1B Q00975 1/20 0.31
APBA1 Q02410 1/20 0.31
CA1 P00915 1/20 0.31
CA2 P00918 1/20 0.31
CA7 P43166 1/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
HDAC2 Q92769 1/20 0.31
LMNA P02545 1/20 0.30
GAA P10253 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1774248 0.87 FNTA (0.35) FNTAFNTBGRIK1GRIK2
SCHEMBL541955 0.80 GRIK1 (0.33) GRIK1GRIK2CYP3A4TDP1CYP2C19
SCHEMBL6394261 0.80 GRIK1 (0.33) GRIK1GRIK2CYP3A4TDP1CYP2C19
Ammonia Solution, Strong SCHEMBL546579 0.78 GRIK1 (0.32) GRIK1GRIK2CYP3A4TDP1CYP2C19
SCHEMBL7197484 0.78
SCHEMBL9302677 0.78 GRIK1 (0.32) GRIK1GRIK2CYP3A4TDP1CYP2C19
SCHEMBL5163974 0.78 GRIK1 (0.32) GRIK1GRIK2CYP3A4TDP1CYP2C19
Ammonia Solution, Strong SCHEMBL9302589 0.78 GRIK1 (0.32) GRIK1GRIK2CYP3A4TDP1CYP2C19
SCHEMBL11033470 0.76 MAPT (0.35) FNTAFNTBTDP1TSHRMAPT
SCHEMBL170785 0.76

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2164885-A None JP disclosed
US-20090286791-A1 Amide Compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-19 US disclosed
EP-2044055-A2 AMIDE COMPOUNDS Takeda Pharmaceutical Company Limited (JP) 2009-04-08 EP disclosed
WO-2008011131-A2 AMIDE COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-01-24 WO disclosed
US-7090704-B2 Method of treating natural or synthetic polyamide fibre materials CIBA SPECIALTY CHEMICALS CORPORATION (US) 2006-08-15 US disclosed
EP-0957197-B1 Process for treating natural or synthetic polyamide fibrous materials CIBA SC HOLDING AG (CH) 2006-06-21 EP disclosed
EP-1458925-B1 METHOD OF TREATING NATURAL OR SYNTHETIC POLYAMIDE FIBRE MATERIALS CIBA SC HOLDING AG (CH) 2006-06-14 EP disclosed
US-20050076452-A1 Method of treating natural or synthetic polyamide fibre materials HUNTSMAN INTERNATIONAL LLC 2005-04-14 US disclosed
EP-1458925-A1 METHOD OF TREATING NATURAL OR SYNTHETIC POLYAMIDE FIBRE MATERIALS Ciba SC Holding AG (CH) 2004-09-22 EP disclosed
EP-0879916-B1 Process for the treatment of fibrous materials made from natural or synthetic polyamide CIBA SC HOLDING AG (CH) 2003-06-25 EP disclosed
EP-0665326-A2 Process for printing fibrous material by direct printing CIBA-GEIGY AG (CH) 1995-08-02 EP disclosed
EP-0639665-A1 Phosphate-free reducing and bleaching agent CIBA-GEIGY AG (CH) 1995-02-22 EP disclosed
EP-0636743-A2 Process for dyeing of wool-containing fibre materials CIBA-GEIGY AG (CH) 1995-02-01 EP disclosed
EP-0631008-A1 Process for the washing of printings or dyeings on cellulose containing textile materials CIBA-GEIGY AG (CH) 1994-12-28 EP disclosed
US-5376148-A Using a paste comprising a water soluble polymer containing sulfo groups, a deaerator, an anionic or nonionic dispersant and an alkanol CIBA-GEIGY CORPORATION (US) 1994-12-27 US disclosed
US-5356442-A Method for dyeing fibrous materials made of or containing wool CIBA-GEIGY CORPORATION (US) 1994-10-18 US disclosed
EP-0582550-A1 Process for dyeing of wool-containing fibrous materials CIBA-GEIGY AG (CH) 1994-02-09 EP disclosed
EP-0581736-A1 Process for printing fibrous material by direct printing CIBA-GEIGY AG (CH) 1994-02-02 EP disclosed
EP-0566537-A1 Process for printing of synthetic fibrous material with transfer-printing CIBA-GEIGY AG (CH) 1993-10-20 EP disclosed
JP-H02164885-A CIS-PLATINUM COMPLEX CONTAINING 1,3-DIAMINOPROPANE DERIVATIVE AS LIGAND BEHRINGWERKE AG 1990-06-25 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286791-A1 Amide Compounds DLAT, DGAT2, DGAT1 FNTA 129/4885FNTB 158/4885GRIK1 633/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.